Effectiveness and Costs of Bevacizumab vs Ranibizumab in DMEEffectiveness and Costs of Bevacizumab vs Ranibizumab in DME

A new head-to-head trial compares the efficacy and economic value of these two anti-VEGF agents for DME. Which one has the edge? BMC Ophthalmology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news